fluticasonesalmeterol sold brand name advair among others fixeddose combination medication containing fluticasone propionate used management asthma chronic obstructive pulmonary disease used inhaling medication common side effects include thrush headache serious side effects may include worsening asthma anaphylaxis seizures heart safety pregnancy breastfeeding fluticasone corticosteroid works decreasing inflammation salmeterol longacting betaadrenoceptor agonist laba works activating adrenergic combination approved medical use united states generic version approved united states commonly prescribed medication united states million fluticasone corticosteroid antiinflammatory component combination decreases inflammation lungs leads improvement breathing salmeterol laba treats constriction airways combination meant used maintenance therapy rescue therapy sudden symptoms common side effects combination individual drugs instance use inhaled corticosteroids associated oral candidiasis commonly known yeast infection thrush rinsing mouth water inhaling medication decreases risk developing condition use inhaled steroids laba recommended resulting improvement control symptoms concerns raised salmeterol may increase risk death due asthma additional risk reduced addition inhaled side effects drug combination may include increased blood pressure change heart rate irregular heartbeat increased risk osteoporosis cataracts studies demonstrated safety inhaled fluticasone propionate children systematic review published found significant adverse effect function axis growth bone mineral density asthmatic children inhaled fluticasone used three fluticasonesalmeterol contains fluticasone propionate synthetic corticosteroid salmeterol selective longacting betaadrenergic receptor agonist fluticasone works potent antiinflammatory agent inhibiting multiple cell types mast cells eosinophils basophils lymphocytes macrophages neutrophils contribute inflammation large component pathogenesis asthma salmeterol works stimulating intracellular adenyl cyclase acts catalyst production cyclic amp increased cyclic amp levels lead relaxation bronchial smooth muscles additionally cyclic amp inhibits release mediators immediate january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product seffalair spiromax intended treatment applicant medicinal product teva chmp also recommended granting marketing authorization duplicate product bropair seffalair spiromax bropair spiromax approved medical use european union march january fda granted mylan nv first generic approval advair advair part larger civil settlement agreement glaxosmithkline gsk united states gsk agreed pay billion united states said gsk promoted offlabel uses advair paid kickbacks healthcare professionals sell drug among httpsenwikipediaorgwikifluticasonesalmeterol